Accel Research Sites recruiting smokers for cessation study - Accel Research Sites

Create a Profile

I accept digital forms of communication(Required)
Hidden
Hidden
This field is for validation purposes and should be left unchanged.
Create a Profile
I accept digital forms of communication(Required)
Hidden
Hidden
This field is for validation purposes and should be left unchanged.

Get In Touch Mobile

I accept digital forms of communication(Required)
This field is for validation purposes and should be left unchanged.

FIND A TRIAL NEAR YOU

No location found for this Zip Code

-- or --

No location found for this Location

FIND A TRIAL NEAR YOU

No location found for this Zip Code

-- or --

No location found for this Location
Back
Date Published: 03/22/2022

Accel Research Sites recruiting smokers for cessation study

DeLand trial seeks current daily smokers 18 and older who want to quit smoking

While rates of smoking in adults in the U.S. have declined over the last decade, millions of people still smoke. And for those who do and want to quit smoking, it can still be a struggle.

Those people will soon have a new resource available to them via a clinical trial at Accel Research Sites. Accel Research Sites will be conducting a study for an investigational medicine, which is meant to reduce withdrawal side effects for those trying to quit smoking.

The trial will take place at the DeLand site with Dr. Bruce Rankin at the principal investigator.

“Quitting smoking can feel impossible,” Dr. Rankin said. “This trial is a great example of how clinical trials can be beneficial to many people and give them access to the latest support and resources in medicine. We hope it is able to make a big difference.”

The investigational medicine partially mimics nicotine in the body, helping to reduce the feeling that participants want more and making it easier to overcome withdrawal side effects that often prevent people from quitting smoking. The drug will be administered by a pill taken three times daily.

Participants will be monitored over the course of 24 weeks and will be compensated for time and travel. Those 18 and older who currently smoke daily and who have tried to quit previously are eligible for the trial.

The double-blind study will give participants a two-in-three chance of receiving the medicine, while one in three will receive a placebo.

Back

Ready to be part of healthcare history? Find the right clinical trial for you.

Get In Touch

I accept digital forms of communication(Required)
This field is for validation purposes and should be left unchanged.
Accessibility Adjustment

Color Adjustment

Orientation Adjustment

Font Size

 

Line height